The Quality Lowdown: Blast From Past At Sun Mohali, Touch Of Future With IT/OT Integration
Executive Summary
Ranbaxy consent decree is invoked again after the FDA’s latest inspection unveils backdating at Sun’s Mohali plant. FDA probes Intas plant’s many deceptions, Ipca stumbles on investigations without start dates and Sure-Biochem must admit missing client’s contamination.
You may also be interested in...
Intas’ Response To Second Data Integrity Inspection Still Did Not Go Far Enough, US FDA Says
Intas – the the troubled Indian firm at the center of the cisplatin shortage – may have punished workers for their visual-inspection subterfuge, but it also should have gone after managers, the FDA asserted in a second data integrity warning letter in four months.
Non-Compendial Product Quality Screening Draws US FDA’s Criticism
Third-party screening of US-marketed drug products is worse than pointless if done with subpar test methods, agency tells PDA/FDA meeting. Meanwhile, release-testing with such methods has been triggering warning letters.
Non-Compendial Product Quality Screening Draws US FDA’s Criticism
Third-party screening of US-marketed drug products is worse than pointless if done with subpar test methods, agency tells PDA/FDA meeting. Meanwhile, release-testing with such methods has been triggering warning letters.